The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

被引：0

作者：

Jimenez-Fonseca, Paula ^{[2
]}

Foy, Victoria ^{[3
]}

Raby, Sophie

Carmona-Bayonas, Alberto ^{[1
]}

Macia-Rivas, Lola ^{[4
]}

Arrazubi, Virginia ^{[5
]}

Cacho Lavin, Diego ^{[6
]}

Hernandez San Gil, Raquel ^{[7
]}

Custodio, Ana ^{[10
]}

Cano, Juana Maria ^{[9
]}

Fernandez Montes, Ana ^{[8
,11
]}

Mirallas, Oriol ^{[12
]}

Macias Declara, Ismael ^{[13
]}

Vidal Tocino, Rosario ^{[14
]}

Visa, Laura ^{[15
]}

Limon, Maria Luisa ^{[16
]}

Pimentel, Paola ^{[17
]}

Martinez Lago, Nieves ^{[18
]}

Sauri, Tamara ^{[19
]}

Martin Richard, Marta ^{[20
]}

Mangas, Monserrat ^{[21
]}

Gil Raga, Mireia

Calvo, Aitana ^{[22
]}

Reguera, Pablo ^{[23
]}

Granja, Monica ^{[24
,25
]}

Martin Carnicero, Alfonso ^{[26
]}

Hernandez Perez, Carolina ^{[27
]}

Cerda, Paula ^{[28
]}

Gomez Gonzalez, Lucia ^{[29
]}

Garcia Navalon, Francisco

Pacheco Barcia, Vilma ^{[30
]}

Gutierrez Abad, David ^{[31
]}

Ruiz Martin, Maribel ^{[32
]}

Weaver, Jamie ^{[33
]}

Mansoor, Wasat ^{[33
]}

Gallego, Javier ^{[34
]}

机构：

[1] Hosp Univ Morales Meseguer, Dept Hematol & Oncol Med, Calle Marques Velez S-N, Murcia 30800, Spain

[2] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Spain

[3] Christie Hosp, Dept Pathol, Manchester, Lancs, England

[4] Hosp Univ Cent Asturias, Pharm Dept, Oviedo, Spain

[5] Complejo Hosp Navarra, IdisNA Navarra Inst Hlth Res, Dept Pathol, Pamplona, Spain

[6] Hosp Univ Marques Valdecilla, Med Oncol Dept, IDIVAL, Santander, Spain

[7] Hosp Univ Canarias, Oncol Dept, Tenerife, Spain

[8] Hosp Univ La Paz, Med Oncol Dept, CIBERONC CB16-12-00398, Madrid, Spain

[9] Hosp Gen Univ Ciudad Real, Dept Nucl Med, Ciudad Real, Spain

[10] Complexo Hospitalario Univ Ourense, Dept Med Oncol, Orense, Spain

[11] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

[12] Consorcio Hosp Univ Parc Tauli, Dept Med Oncol, Sabadell, Spain

[13] Complejo Asistencial Univ Salamanca, Dept Hematol, IBSAL, Salamanca, Spain

[14] Hosp Mar, Med Oncol Dept, Barcelona, Spain

[15] Hosp Univ Virgen Rocio, Med Oncol Dept, Seville, Spain

[16] St Lucia Univ Gen Hosp, Radiat Oncol Dept, Cartagena, Spain

[17] Complejo Hospitalario Univ A Coruna, Dept Med Oncol, La Coruna, Spain

[18] IDIBAPS, Hosp Clin, Dept Med Oncol, Barcelona, Spain

[19] Catalan Inst Oncol, Med Oncol Dept, Barcelona, Spain

[20] Hosp Galdakao Usansolo, Serv Angiol & Cirugia Vasc, Usansolo, Spain

[21] Consorcio Hosp Gen Univ Valencia, Med Oncol Dept, Valencia, Spain

[22] Hosp Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain

[23] Hosp Univ Ramon & Cajal, Med Oncol Dept, Madrid, Spain

[24] Hosp Univ Clin San Carlos, Med Oncol Dept, Madrid, Spain

[25] Hosp San Pedro, Med Oncol, Logrono, Spain

[26] Hosp Univ Nuestra Senora Candelaria, Med Oncol Dept, Santa Cruz De Tenerife, Spain

[27] Hosp Univ St Creu i St Pau, Dept Immunol, Barcelona, Spain

[28] Hosp Gen Univ Alicante, Dept Med Oncol, Alicante, Spain

[29] Hosp Univ Son Llatzer, Internal Med Dept, Palma De Mallorca, Spain

[30] Hosp Univ Torrejon, Med Oncol Dept, Madrid, Spain

[31] Hosp Univ Fuenlabrada, Dept Med Oncol, Madrid, Spain

[32] Rio Carr Hosp, Palencia, Spain

[33] Univ Manchester, Christie Hosp, Dept Med Oncol, Manchester, England

[34] Univ Elche, Dept Med Oncol, Gen Hosp, Elche 03203, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2023年 / 15卷

关键词：

gastric cancer; HER2-positive; nomogram; oesophageal cancer; survival; trastuzumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab.Methods: Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK).Results: In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7.76 [95% confidence interval (CI), 7.13-8.25] and 14.0 months (95% CI, 13.0-14.9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0.606 (95% CI, 0.578-0.636) and 0.623 (95% CI, 0.594-0.655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0.650 and 0.683 for PFS and OS, respectively.Conclusion: The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints.

引用

页数：16

共 50 条

[1] The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Jimenez-Fonseca, Paula
Foy, Victoria
Raby, Sophie
Carmona-Bayonas, Alberto
Macia-Rivas, Lola
Arrazubi, Virginia
Lavin, Diego Cacho
Gil, Raquel Hernandez San
Custodio, Ana
Cano, Juana Maria
Montes, Ana Fernandez
Mirallas, Oriol
Declara, Ismael Macias
Tocino, Rosario Vidal
Visa, Laura
Limon, Maria Luisa
Pimentel, Paola
Lago, Nieves Martinez
Sauri, Tamara
Richard, Marta Martin
Mangas, Monserrat
Gil Raga, Mireia
Calvo, Aitana
Reguera, Pablo
Granja, Monica
Carnicero, Alfonso Martin
Perez, Carolina Hernandez
Cerda, Paula
Gonzalez, Lucia Gomez
Navalon, Francisco Garcia
Barcia, Vilma Pacheco
Abad, David
Martin, Maribel Ruiz
Weaver, Jamie
Mansoor, Wasat
Gallego, Javier
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[2] External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
Jimenez-Fonseca, Paula
Carmona-Bayonas, Alberto
Martinez-Torron, Alba
Alsina, Maria
Custodio, Ana
Serra, Olbia
Cacho Lavin, Diego
Limon, Maria Luisa
Sauri, Tamara
Lopez, Flora
Visa, Laura
Granja, Monica
Martinez Lago, Nieves
Arrazubi, Virginia
Vidal Tocino, Rosario
Hernandez, Raquel
Aguado, Gema
Cano, Juana Maria
Martin Carnicero, Alfonso
Mangas, Monserrat
Pimentel, Paola
Fernandez Montes, Ana
Macias Declara, Ismael
Longo, Federico
Ramchandani, Avinash
Martin Richard, Marta
Hurtado, Alicia
Azkarate, Aitor
Hernandez Perez, Carolina
Serrano, Raquel
Gallego, Javier
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[3] Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
Kadowaki, Shigenori
Masuishi, Toshiki
Eto, Tetsuya
Narita, Yukiya
Taniguchi, Hiroya
Ura, Takashi
Ando, Masashi
Tajika, Masahiro
Niwa, Yasumasa
Yatabe, Yasushi
Muro, Kei
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 807 - 813
[4] Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
Shigenori Kadowaki
Toshiki Masuishi
Tetsuya Eto
Yukiya Narita
Hiroya Taniguchi
Takashi Ura
Masashi Ando
Masahiro Tajika
Yasumasa Niwa
Yasushi Yatabe
Kei Muro
Cancer Chemotherapy and Pharmacology, 2017, 80 : 807 - 813
[5] Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
A Custodio
A Carmona-Bayonas
P Jiménez-Fonseca
M L Sánchez
A Viudez
R Hernández
J M Cano
I Echavarria
C Pericay
M Mangas
L Visa
E Buxo
T García
A Rodríguez Palomo
F Álvarez Manceñido
A Lacalle
I Macias
A Azkarate
A Ramchandani
A Fernández Montes
C López
F Longo
R Sánchez Bayona
M L Limón
A Díaz-Serrano
A Hurtado
R Madero
C Gómez
J Gallego
British Journal of Cancer, 2017, 116 : 1526 - 1535
[6] Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
Custodio, A.
Carmona-Bayonas, A.
Jimenez-Fonseca, P.
Sanchez, M. L.
Viudez, A.
Hernandez, R.
Cano, J. M.
Echavarria, I.
Pericay, C.
Mangas, M.
Visa, L.
Buxo, E.
Garcia, T.
Rodriguez Palomo, A.
Alvarez Mancenido, F.
Lacalle, A.
Macias, I.
Azkarate, A.
Ramchandani, A.
Fernandez Montes, A.
Lopez, C.
Longo, F.
Sanchez Bayona, R.
Limon, M. L.
Diaz-Serrano, A.
Hurtado, A.
Madero, R.
Gomez, C.
Gallego, J.
BRITISH JOURNAL OF CANCER, 2017, 116 (12) : 1526 - 1535
[7] Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
Montemurro, Filippo
Donadio, Michela
Clavarezza, Matteo
Redana, Stefania
Jacomuzzi, Maria Elena
Valabrega, Giorgio
Danese, Saverio
Vietti-Ramus, Guido
Durando, Antonio
Venturini, Marco
Aglietta, Massimo
ONCOLOGIST, 2006, 11 (04) : 318 - 324
[8] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
Del Mastro, Lucia
Lambertini, Matteo
Bighin, Claudia
Levaggi, Alessia
D'Alonzo, Alessia
Giraudi, Sara
Pronzato, Paolo
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
[9] MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients
Lote, Hazel
Mousoullou, Florentia
Vlachogiannis, George
Lampis, Andrea
Satchwell, Laura
Peckitt, Clare
Fong, Caroline
Begum, Ruwaida
Kidd, Shannon
Cromarty, Susan
Gordon, Anderley
Fribbens, Charlotte
Rao, Sheela
Starling, Naureen
Chau, Ian
Cunningham, David
Valeri, Nicola
FRONTIERS IN ONCOLOGY, 2023, 13
[10] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
Chang, Helena R.
CANCER, 2010, 116 (12) : 2856 - 2867

← 1 2 3 4 5 →